查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1747658

全球第三代定序市场

Third Generation Sequencing
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 271 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到2030年，全球第三代定序市场规模将达25亿美元

全球第三代定序市场规模预计在2024年达到7.858亿美元，预计到2030年将达到25亿美元，2024年至2030年的复合年增长率为21.2%。本报告分析的细分市场之一－第三代定序产品，预计其复合年增长率为22.8%，到分析期结束时规模将达到18亿美元。第三代定序服务细分市场在分析期间的复合年增长率预计为17.4%。

美国市场规模估计为 2.066 亿美元，中国市场预计复合年增长率为 20.0%

美国第三代定序市场规模预计在2024年达到2.066亿美元。预计到2030年，作为世界第二大经济体的中国市场规模将达到3.802亿美元，在2024-2030年的分析期内，复合年增长率为20.0%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为19.6%和18.1%。在欧洲，预计德国市场的复合年增长率约为14.4%。

全球「第三代定序」市场—主要趋势与驱动因素摘要

精准基因体学时代的第三代定序有何特色？

第三代定序 (TGS) 技术透过提供无需扩增的长读长单分子序列，重新定义了基因组分析的模式。这种基于以往定序技术的演进对生物学研究、临床诊断、农业和演化科学产生了深远的影响。与严重依赖短读长和易出错的扩增过程的第二代技术不同，TGS 平台（例如 Pacific Biosciences 的 SMRT 和 Oxford Nanopore 的 MinION）能够在包含重复序列、结构变异和表观遗传修饰的复杂基因组区域提供超长读长和更高保真度的定序。这些能力对于从头组装完整基因组至关重要，尤其是在植物基因组、罕见疾病遗传学和癌症异质性等先前颇具挑战性的领域。研究人员也将 TGS 应用于转录组学，其中全长 mRNA定序可以精确检测可变剪接和异构体表达。此外，TGS 还提供即时定序，可实现快速的周转时间，这在感染疾病爆发期间以及在病原体监测和生物安全应用中至关重要。在定序过程中直接读取 RNA 并检测甲基化模式的能力使 TGS 成为基础研究和临床环境中的革命性技术。

即时可携式定序是基因组诊断的未来吗？

便携性和即时分析是TGS平台的标誌，在临床和现场环境中均提供无与伦比的灵活性。像Oxford Nanopore MinION这样的设备足够小巧，可以放进口袋，但功能又足够强大，可以在野外进行复杂的基因组测序，无论是在偏远的村庄、战场还是太空站。这对公共卫生、流行病学和个人化医疗具有巨大的意义。在临床诊断中，即时定序可以快速识别病原体，这对于败血症管理、医院内感染和癌症分析至关重要。在COVID-19大流行期间，TGS平台已在全球范围内部署，用于即时病毒基因组追踪，证明了其在监测突变和指南公共卫生应对方面的价值。在法医学，TGS为DNA分析提供了一个新的精确度和整体性维度。可携式平台还使农业科学家能够在野外监测动植物基因组，有助于即时育种决策、疾病检测和生物工程。这种移动性与即时数据输出相结合，大大减少了对集中实验室的需求，使得在资源有限的环境中也能进行高级测序，并为分散、快速和数据丰富的诊断打开了大门。

哪些技术进步推动了第三代定序的应用？

TGS 的进步是由分子生物学、生物资讯学和仪器工程的改进融合所驱动的。关键的发展包括提高通量、降低错误率和增强碱基调用演算法，使 TGS 平台能够匹配第二代准确度，同时保持长读取的优势。新酶化学、孔设计和讯号处理方法的引入增加了读取长度和速度，同时降低了每个碱基的成本。生物资讯工具也得到了发展，提供了可扩展的解决方案来处理 TGS 生成的庞大而复杂的数据集，而云端基础的平台促进了即时基因组数据的分析和共用。多路復用功能得到了扩展，使研究人员能够同时对多个样本进行测序而不会影响准确性。此外，样品製备和自动化方面的创新正在减少劳动时间和污染风险。一些 TGS 工具的开放平台特性促进了广泛的学术和工业合作，加速了特定应用的发现和客製化。这种技术势头使得TGS不仅成为旧方法的替代品，而且成为整个科学频谱尖端研究和商业性突破的多功能推动者。

第三代测序市场的成长受到多种因素的推动。

第三代定序市场快速扩张是由技术、应用和行为动态共同驱动的。在医疗保健领域，对精准诊断和个人化治疗计划日益增长的需求需要能够检测复杂结构突变、罕见突变和表观遗传标记的定序工具。在肿瘤学领域，即时和全面定序正在加速向个人化癌症治疗的转变。在感染疾病监测中，TGS 能够对病原体进行近乎即时的基因组分析。由于新出现的抗生素抗药性菌株的增加，这种需求尤其迫切。在农业领域，对粮食安全和基因优化作物的追求刺激了 TGS 在植物和动物基因组分析中的应用。此外，直接面向消费者的基因检测日益普及，引起了人们对能够提供更深入见解的全面定序技术的兴趣。为了反映向高解析度、高通量基因组科学的更广泛转变，学术机构和生物技术新兴企业越来越多地将 TGS 平台纳入其研究基础设施。此外，利用行动装置进行定序的去中心化正在改变使用者行为，并推动照护现场诊断和资料存取的民主化。这种技术主导和终端用户特定的动态正在推动市场强劲的成长轨迹。

部分

组件（产品、服务）、技术（单分子即时定序、奈米孔定序、合成长读定定序）、应用（基因测序、表观遗传学、转录组学、总体基因体学、其他应用）、最终用户（生物製药公司、医院/诊所、合约研究组织、其他最终用户）

受访公司范例（值得关注的34家公司）

  • 10x Genomics
  • Agilent Technologies, Inc.
  • BGI Genomics Co., Ltd.
  • Complete Genomics, Inc.
  • Element Biosciences, Inc.
  • Eurofins Scientific
  • F. Hoffmann-La Roche AG
  • GATC Biotech AG
  • GenapSys, Inc.
  • Genia Technologies, Inc.
  • Illumina, Inc.
  • Loop Genomics
  • Nabsys, Inc.
  • Oxford Nanopore Technologies
  • Pacific Biosciences of California, Inc.
  • PerkinElmer, Inc.
  • Phase Genomics, Inc.
  • QIAGEN NV
  • Stratos Genomics, Inc.
  • Thermo Fisher Scientific Inc.

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口（成品和原始OEM）来预测其竞争地位的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括人为提高销货成本、盈利下降、供应链重组以及其他微观和宏观市场动态。

全球产业分析师密切关注来自全球顶尖首席经济学家（14,949位）、智库（62家）以及贸易和产业协会（171家）的专家的意见，以评估其对生态系统的影响并应对新的市场现实。我们追踪了来自每个主要国家的专家和经济学家对关税及其对本国影响的看法。

全球产业分析师预计，这场动盪将在未来2-3个月内逐渐平息，新的世界秩序将更加清晰地建立。全球产业分析师正在即时追踪这些事态发展。

2025年4月：谈判阶段

在4月的报告中，我们将探讨关税对全球整体市场的影响，并提供区域市场调整。我们的预测是基于历史数据和不断变化的市场影响因素。

2025年7月：最终关税调整

在各国宣布最终重置后，客户将在 7 月收到免费更新，最终更新将包含明确的关税影响分析。

相互和双边贸易及关税影响分析：

美国<>中国<>墨西哥<>加拿大<>欧盟<>日本<>印度<>其他176个国家

领先的产业经济学家：全球产业分析师知识库追踪了 14,949 位经济学家，其中包括来自民族国家、智库、贸易和产业协会、大型企业以及各领域专家的最具影响力的首席经济学家，他们共用了这场前所未有的全球经济状况模式转移的影响。我们超过 16,491 份报告大多遵循基于里程碑的两阶段发布计划。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他地区

第四章 竞赛

简介目录
Product Code: MCP35878

Global Third Generation Sequencing Market to Reach US$2.5 Billion by 2030

The global market for Third Generation Sequencing estimated at US$785.8 Million in the year 2024, is expected to reach US$2.5 Billion by 2030, growing at a CAGR of 21.2% over the analysis period 2024-2030. Third Generation Sequencing Products, one of the segments analyzed in the report, is expected to record a 22.8% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Third Generation Sequencing Services segment is estimated at 17.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$206.6 Million While China is Forecast to Grow at 20.0% CAGR

The Third Generation Sequencing market in the U.S. is estimated at US$206.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$380.2 Million by the year 2030 trailing a CAGR of 20.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.6% and 18.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.4% CAGR.

Global "Third Generation Sequencing" Market - Key Trends & Drivers Summarized

What Sets Third Generation Sequencing Apart in the Era of Genomic Precision?

Third Generation Sequencing (TGS) technologies have redefined the landscape of genomic analysis by offering long-read, single-molecule sequencing without the need for amplification. This evolution from earlier sequencing technologies has profound implications for biological research, clinical diagnostics, agriculture, and evolutionary science. Unlike second-generation methods, which rely heavily on short reads and error-prone amplification processes, TGS platforms such as Pacific Biosciences’ SMRT and Oxford Nanopore’s MinION deliver ultra-long reads with higher fidelity across complex genomic regions, including repetitive sequences, structural variants, and epigenetic modifications. These capabilities are critical for assembling complete genomes de novo, especially in previously intractable areas like plant genomes, rare disease genetics, and cancer heterogeneity. Researchers are also applying TGS to transcriptomics for full-length mRNA sequencing, allowing for accurate detection of alternative splicing and isoform expression. Additionally, TGS offers real-time sequencing, enabling rapid turnaround times critical during infectious disease outbreaks and for applications in pathogen surveillance and biosecurity. The ability to directly read RNA and detect methylation patterns during sequencing positions TGS as a transformative technology in both foundational research and clinical practice.

Is Real-Time and Portable Sequencing the Future of Genomic Diagnostics?

Portability and real-time analysis are hallmarks of TGS platforms, offering unmatched flexibility in both clinical and field environments. Devices like the Oxford Nanopore MinION are compact enough to fit in a pocket yet powerful enough to perform complex genomic sequencing on-site-be it a remote village, a battlefield, or a space station. This has enormous implications for public health, epidemiology, and personalized medicine. In clinical diagnostics, real-time sequencing enables faster pathogen identification, crucial in sepsis management, hospital-acquired infections, and cancer profiling. During the COVID-19 pandemic, TGS platforms were deployed globally for real-time viral genome tracking, showcasing their value in monitoring mutations and guiding public health responses. In forensic science, TGS offers new dimensions of accuracy and comprehensiveness for DNA profiling. Portable platforms are also enabling agricultural scientists to monitor plant and animal genomes in the field, aiding in real-time breeding decisions, disease detection, and bioengineering. This mobility-combined with real-time data output-greatly reduces the need for centralized laboratories, making advanced sequencing accessible even in resource-limited settings and opening the door to decentralized, rapid, and data-rich diagnostics.

What Are the Technological Advancements Driving Adoption of Third Generation Sequencing?

The progress in TGS is driven by a convergence of improvements in molecular biology, bioinformatics, and instrument engineering. Key developments include increased throughput, reduced error rates, and enhanced basecalling algorithms that now allow TGS platforms to rival second-generation accuracy while preserving the advantages of long reads. The introduction of new enzyme chemistries, pore designs, and signal processing methods has improved read lengths and speed, while simultaneously lowering costs per base. Bioinformatics tools have also advanced, offering scalable solutions to handle the vast and complex datasets generated by TGS, with cloud-based platforms facilitating real-time genomic data analysis and sharing. Multiplexing capabilities are expanding, allowing researchers to sequence multiple samples concurrently without compromising accuracy. Additionally, innovations in sample preparation and automation are reducing hands-on time and contamination risks. The open-platform nature of some TGS tools has encouraged broad academic and industrial collaboration, accelerating discovery and customization for specific applications. This technological momentum is positioning TGS not just as a replacement for older methods, but as a versatile enabler of cutting-edge research and commercial breakthroughs across a spectrum of scientific disciplines.

The Growth in the Third Generation Sequencing Market Is Driven by Several Factors…

The rapid expansion of the third generation sequencing market is being fueled by a combination of technological, application-specific, and behavioral dynamics. In the healthcare sector, the increasing demand for precision diagnostics and personalized treatment plans is necessitating sequencing tools capable of detecting complex structural variations, rare mutations, and epigenetic markers-capabilities where TGS outperforms conventional methods. In oncology, real-time and comprehensive sequencing is accelerating the shift toward individualized cancer therapies. In infectious disease surveillance, TGS enables near-instantaneous genomic analysis of pathogens, a need that has become especially urgent with the rise of emerging and antibiotic-resistant strains. In agriculture, the push for food security and genetically optimized crops is spurring adoption of TGS in plant and animal genomics. Furthermore, the growing popularity of direct-to-consumer genetic testing is driving interest in more comprehensive sequencing technologies that offer deeper insights. Academic institutions and biotech startups are increasingly incorporating TGS platforms into their research infrastructures, reflecting a broader transition to high-resolution, high-throughput genomic science. The decentralization of sequencing-empowered by portable devices-is also transforming user behavior, encouraging point-of-care diagnostics and democratized data access. These technology-driven and end-use-specific dynamics are collectively propelling the market’s robust growth trajectory.

SCOPE OF STUDY:

The report analyzes the Third Generation Sequencing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Products, Services); Technology (Single-molecule Real-time Sequencing, Nanopore Sequencing, Synthetic Long-read Sequencing); Application (Genome Sequencing, Epigenetics, Transcriptomics, Metagenomics, Other Applications); End-User (Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

  • 10x Genomics
  • Agilent Technologies, Inc.
  • BGI Genomics Co., Ltd.
  • Complete Genomics, Inc.
  • Element Biosciences, Inc.
  • Eurofins Scientific
  • F. Hoffmann-La Roche AG
  • GATC Biotech AG
  • GenapSys, Inc.
  • Genia Technologies, Inc.
  • Illumina, Inc.
  • Loop Genomics
  • Nabsys, Inc.
  • Oxford Nanopore Technologies
  • Pacific Biosciences of California, Inc.
  • PerkinElmer, Inc.
  • Phase Genomics, Inc.
  • QIAGEN N.V.
  • Stratos Genomics, Inc.
  • Thermo Fisher Scientific Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Third Generation Sequencing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Demand for Real-Time, Long-Read Sequencing Propels Market Growth
    • Accelerated Adoption in Clinical Diagnostics Expands Addressable Market
    • Rising Incidence of Genetic Disorders and Cancer Drives Sequencing Uptake
    • Demand for Deeper Genome Insights Strengthens Business Case for Third Gen Platforms
    • Government Genomic Initiatives and Grants Spur R&D and Market Entry
    • Advances in Bioinformatics Tools Enhance Accuracy and Usability of Sequencing Data
    • Growing Use in Agriculture and Animal Genomics Broadens Market Scope
    • Declining Cost per Genome Sequenced Drives Mass Adoption
    • Personalized Medicine Boom Throws Spotlight on Rapid Sequencing Technologies
    • Emerging Use Cases in Pathogen Surveillance Sustain Market Momentum
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Third Generation Sequencing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Third Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Third Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Third Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Genome Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Genome Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Genome Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Epigenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Epigenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Epigenetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Transcriptomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Transcriptomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Transcriptomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Metagenomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Metagenomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Metagenomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Single-molecule Real-time Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Single-molecule Real-time Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Single-molecule Real-time Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Nanopore Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Nanopore Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Nanopore Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Synthetic Long-read Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Synthetic Long-read Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Synthetic Long-read Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 47: USA Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • JAPAN
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • CHINA
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: China 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • EUROPE
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Third Generation Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Third Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Europe 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • FRANCE
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 110: France Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: France 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: France 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 119: France Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: France Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: France 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • GERMANY
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Germany 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Germany 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Germany 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Italy 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Italy 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Italy 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 146: UK Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: UK 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: UK 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: UK 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 155: UK Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: UK 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Europe Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Europe 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Europe Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Europe 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Europe Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Europe 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Europe Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Europe 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Asia-Pacific Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Asia-Pacific 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Asia-Pacific Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Asia-Pacific 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Asia-Pacific Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Asia-Pacific 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 179: Asia-Pacific Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Asia-Pacific Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Asia-Pacific 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 182: Rest of World Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of World Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of World 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of World Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of World Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of World 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of World Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of World Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of World 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of World Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of World Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of World 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030

IV. COMPETITION